Impact of lipid-lowering therapy with Evolocumab on coronary plaque regression in patients with coronary artery disease
Not Applicable
- Conditions
- Patients with coronary artery disease requiring percutaneous coronary intervention (PCI), and with LDL-C >= 100 mg/dl even on statin therapy for at least 4 weeks
- Registration Number
- JPRN-UMIN000023448
- Lead Sponsor
- Chiba University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Not provided
Exclusion Criteria
1) Difficulty to observe the coronary arteries, including non-culprit lesions, by IVUS at PCI procedure 2) Severe hepatic insufficiency 3) Severe renal insufficiency 4) Severe heart failure (left ventricular ejection fraction <30%, or NYHA class III or IV) 5) intolerance or allergy to statin 6) Pregnant, postpartum within 28 days, or breast-feeding 7) Recognized as inadequate by attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method